Argenx: Jim Daly Steps Down from the Board of Directors After Eight Years
Argenx announces its annual general meeting on May 6, 2026, in the Netherlands. The meeting will include the review of the 2025 financial statements and changes to the board's composition.
The shareholders' general meeting will be held on Wednesday, May 6, 2026, at 1:00 PM CET at the Hilton Amsterdam Schiphol, in Schiphol (Netherlands). In addition to routine items such as the adoption of the annual accounts for 2025, the advisory vote on the 2025 remuneration report, and the discharge of directors for the fiscal year 2025, the agenda includes the authorization for the board to issue shares and to limit or exclude pre-emptive rights related to them.
Jim Daly's Departure from the Board
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Jim Daly will step down from his role as a non-executive director and chairman of the marketing committee effective May 6, 2026. Mr. Daly has served as a non-executive director since May 2018. The board is currently reviewing succession options for the chairmanship of the marketing committee. Shareholders are invited to attend in person or by electronic proxy. The formal notice, complete agenda, and meeting documents are available on www.argenx.com and www.abnamro.com/evoting.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1.3MD€
Net income: 366M€
Guidance from the release
argenx continue de livrer un impact significatif pour les patients.
Argentx affiche une croissance de 63% par rapport à l'année précédente.
Risks mentioned
Les résultats peuvent varier en fonction des incertitudes liées aux essais cliniques.
L'impact des lois et règlements gouvernementaux pourrait affecter les activités.
Opportunities identified
VYVGART pourrait devenir la première thérapie approuvée dans les populations gMG.
Lancement d'une étude pour le candidat pipeline empasiprubart.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
